Lake Wood Hospital
Lakewood, Ohio

2507

Received 23

June 20, 1975

United States Nuclear Regulatory Commission
Leo Wade, Jr., Ph. D.
Materials Branch
Division of Materials and
Fuel Cycle Facility Licensing
Washington, D.C.

Refer to: Control No. 56524
Byproduct Material License No. 34-01197-01

Dear Sir:

In compliance with your request of June 4, 1975, in regard to our application for permission to use technetium 99m Osteoscan Skeletal Imaging Agent (Proctor and Gamble), the following additional information is submitted.

1. All patient doses will be assayed prior to administration to assure that they do not exceed the recommended dose and to further insure at least 90% accuracy of dose. A Radex Mark V Isotope Dosecalibrator will be used to assay technetium activity in the preparation of the Osteoscan, the final preparation and each patient dose.

2. Syringe shields will be used for preparation and administration of patient doses.

3. The areas used for elution of Mo-99-Tc99m generators, for preparation of radiopharmaceuticals from reagent kits and for preparation of individual patient doses will be surveyed for contamination after each procedure and/or at the end of each working day.

4. All personnel who elute Mo-99Tc-99m generators or prepare radiopharmaceuticals from reagent kits will monitor their hands and clothing for contamination after each procedure. In addition all personnel who prepare patient doses or work in areas used for elution of generators, preparation of radiopharmaceuticals or preparation of individual patient doses will monitor their hands and clothing for contamination before leaving those areas.

A46

3

Please note that the above information was included in our original request of May 19, 1975.

Truly yours,

William J. Fayen, M.D.
Nuclear Medicine Department

WJF/md

Lakewood Hospital
Nuclear Medicine Department
Control No. 56524
License No. 34-01197-01